Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Background: In contrast with the setting of acute myocardial infarction, there are limited data regarding the impact of diabetes mellitus on clinical outcomes in contemporary cohorts of patients with chronic coronary syndromes. We aimed to investigate the prevalence and prognostic impact of diabetes according to geographical regions and ethnicity. Methods and results: CLARIFY is an observational registry of patients with chronic coronary syndromes, enrolled across 45 countries in Europe, Asia, America, Middle East, Australia, and Africa in 2009–2010, and followed up yearly for 5 years. Chronic coronary syndromes were defined by ≥1 of the following criteria: prior myocardial infarction, evidence of coronary stenosis >50%, proven symptomatic myocardial ischaemia, or prior revascularization procedure. Among 32 694 patients, 9502 (29%) had diabetes, with a regional prevalence ranging from below 20% in Northern Europe to ∼60% in the Gulf countries. In a multivariable-adjusted Cox proportional hazards model, diabetes was associated with increased risks for the primary outcome (cardiovascular death, myocardial infarction, or stroke) with an adjusted hazard ratio of 1.28 (95% confidence interval 1.18, 1.39) and for all secondary outcomes (all-cause and cardiovascular mortality, myocardial infarction, stroke, heart failure, and coronary revascularization). Differences on outcomes according to geography and ethnicity were modest. Conclusion: In patients with chronic coronary syndromes, diabetes is independently associated with mortality and cardiovascular events, including heart failure, which is not accounted by demographics, prior medical history, left ventricular ejection fraction, or use of secondary prevention medication. This is observed across multiple geographic regions and ethnicities, despite marked disparities in the prevalence of diabetes. ClinicalTrials identifier: ISRCTN43070564
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The estimated global prevalence of diabetes is approximately 30% among patients with chronic coronary syndromes, and thus most people with cardiovascular disease do not have diabetes. 42”
From Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023) · cites this paper as [42]
In the citing paper
“In patients with CCS, T2DM is also associated with an increased risk of the combined outcome (CV death, MI, or stroke) with an adjusted HR of 1.28.39”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [39]
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166 · cited 1×
“previous history of myocardial infarction or history of coronary revascularization and patients with established coronary artery disease who may have no symptoms or ischemia.(17) Patients with chronic coronary syndromes were enrolled from 45 countries in Europe, the Middle East, Asia, Northern, Central and South Ameri…”
BackgroundThe Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Danaei, G., Finucane, M. M., Lu, Y., Singh, G. M., Cowan, M. J., Paciorek, C. J., Lin, J. K., Farzadfar, F., Khang, Y.-H., Stevens, G. A., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60679-x · Cited by 3,568
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 1×
“Notably, SGLT-2 inhibitors have been shown to reduce cardiovascular death and hospitalization for heart failure among patients with or without cardiovascular disease and with or without a history of heart failure.(38,41)”
BackgroundInitial Invasive or Conservative Strategy for Stable Coronary Disease
Maron, D. J., Hochman, J. S., Reynolds, H. R., Bangalore, S., O’Brien, S. M., Boden, W. E., Chaitman, B. R., Senior, R., López-Sendón, J., Alexander, K. P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915922 · Cited by 2,449
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868 · cited 1×
“hospitalization for heart failure when initiated soon after an episode of decompensated heart failure.(42) These improvements are particularly relevant in the context of our finding that patients with diabetes were more likely to be hospitalized for heart failure.”
BackgroundSelf-citationEpidemic obesity and type 2 diabetes in Asia
Yoon, K.-H., Lee, J.-H., Kim, J.-W., Cho, J. H., Choi, Y.-H., Ko, S.-H., Zimmet, P., & Son, H.-Y. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69703-1 · Cited by 1,580 · cited 4×
“Research on the epidemiology of diabetes needs to be combined with efforts in primary prevention of diabetes – weight control and exercise being the first steps –, early detection of the disorder, and improved management of patients with established diabetes, both at the individual level and through health system inte…”
BackgroundInfluentialMcGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235 · cited 2×
“In addition, SGLT-2 inhibitors have been shown to have a marked benefit for kidney disease progression in patients with diabetes.(41,43) Of note, disparities in access to these lifesaving therapies will likely further drive regional differences over time until generic access is widely available.”
BackgroundSotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
Self-citation
Research works printed but not linked: 1
- Roglic, 2016, Global Report on Diabetes
Cited by
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. N., Викторович, А. М., Алексеева, Л. И., Almazova, I. I., Andreenko, Е. Y., Antipushina, D. N., Balanova, Y. А., et al. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3996 · Cited by 65
Серік, С., Mavrycheva, N., & Ченчік, Т. О. (2021) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2021.4.08 · Cited by 59
Parab, P. T., Chaudhary, P., Mukhtar, S., Moradi, A., Kodali, A., Okoye, C., Klein, D., Mohamoud, I., Olanisa, O. O., & Hamid, P. (2023) · Cureus · doi:10.7759/cureus.45487 · Cited by 52
Metadata
- Authors
- Mak, K.-H., Vidal-Petiot, E., Young, R., Sorbets, E., Greenlaw, N., Ford, I., Tendera, M., Ferrari, R., Tardif, J.-C., Udell, J. A., Escobedo, J., Fox, K. M., Steg, P. G., & the CLARIFY Investigators
- Affiliations
- Gleneagles Hospital (SG)
- Physiology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat and INSERM U1149, Centre for Research in Inflammation, 46 rue Henri Huchard, Paris 75018, France
- University of Glasgow (GB)
- Inserm (FR)
- Department of Cardiology and Structural Heart Disease, Medical University of Silesia, Ziolowa Str. 45/47, 40-635 Katowice, Poland
- University of Ferrara (IT)
- Montreal Heart Institute (CA)
- University of Toronto (CA)
- Mexican Social Security Institute (MX)
- Royal Brompton Hospital (GB)
- Université de Paris, 16 rue Henri Huchard, 75018 Paris, France
- ORCID
- Venue
- European Journal of Preventive Cardiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-04-06
- Volume
- 28
- Issue
- 16
- Pages
- 1795-1806
- ISSN
- 2047-4873 (ISSN-L)
- 2047-4881
- OpenAlex
- W3144707062
- Cited by
- 39
- References
- 46
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 11 · 2023: 8 · 2022: 4 · 2021: 2
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- green
- eprints.gla.ac.uk
- Licence
- Locations
- European Journal of Preventive Cardiology (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Servier
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- diabetes mellitus, stable coronary artery disease, diabetes prevalence, cardiovascular mortality, cardiovascular events, myocardial infarction, stroke, heart failure, coronary revascularization, regional variation, ethnic differences, CLARIFY registry
- MeSH terms
- Coronary Artery Disease, Diabetes Mellitus, Ethnicity, Humans, Risk Factors, Stroke Volume, Syndrome, Prevalence, Ventricular Function, Left, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. https://app.cochat.ai/papers/10.1093/eurjpc/zwab011
- The paper
- Mak, K.-H., Vidal-Petiot, E., Young, R., Sorbets, E., Greenlaw, N., Ford, I., Tendera, M., Ferrari, R., Tardif, J.-C., Udell, J. A., Escobedo, J., Fox, K. M., Steg, P. G., & the CLARIFY Investigators. (2022). Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwab011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.